Metsera Drops Unbelievable Data On Their Once-Monthly Pipeline Obesity MedsOn The Pen

Metsera, the $500M startup we covered back in January, wasn’t supposed to make another big move until fall. But today, they quietly dropped a bombshell. Not just more clinical updates, but a clear signal to the entire obesity drug world that they’re not here to play catch up. They’re here to leapfrog.

Let’s break down what they just told investors. Because behind the biotech phrases and finance talk, the message was incredibly meaningful for patients living with obesity.

First, the big news. VESPER 3 results coming early

Back in June, Metsera got people talking. Their lead drug, called MET 097i, showed 11% weight loss after just twelve weeks. Once monthly. That’s a big deal if you find weekly dosing to be a bit annoying.

Today we found out the Phase 2 studies are fully enrolled. And here’s the kicker. We’re getting early data from two of those trials in September. That includes VESPER 1 and the titration arm of VESPER 3. Those results will help Metsera fine tune the dose and launch their global Phase 3 by the end of the year.

That is fast. Really fast.

The amylin curveball

Here comes the swerve. Metsera’s long-acting amylin agonist candidate, MET 233i, just posted numbers that made people do a double take. Over 8% weight loss after five weeks. Let that sit with you.

No one else has done this. Novo’s Cagrilintide was not this effective on its own. Lilly is still barely whispering about their amylin candidates, namely eloralintide. And here’s Metsera showing early signs that a once monthly GLP-1 and amylin combo might exceed the most impressive results we’ve seen yet.

The combo data, MET 233i plus MET 097i, is expected later this year or early next. If it hits, this becomes more than a contender. It becomes a real threat to the current giants.

Orals are still coming

Metsera also reminded us they’re still working on an oral program. MET 097o and MET 224o are the candidates in motion. We’re supposed to get four week weight loss data by the end of the year.

Will it compete with Orforglipron or Rybelsus? We don’t know yet. But if they can prove their oral peptides work, that would be another lane they could potentially disrupt.

Why it matters

If you’re on GLP-1s, trying to get on them, or watching the price tags spiral out of control, today’s update should make you sit up straight.

Metsera now has over $530 million dollars in cash. They don’t need a partner. They don’t need to slow down. They’re playing to win. And they’re not just betting on one molecule. They’re building an entire lineup. Injectables. Combinations. Orals. Even long term quarterly options in preclinical development.

The weight loss numbers so far aren’t shocking. They’re solid. But in today’s market, being solid isn’t enough. Patients are expecting 20% weight loss or more, at a minimum. So the next round of data, especially data that includes realistic, real-world titration schedules will tell the whole story.

Convenience. Tolerability. Simplicity. Affordability. These are the things patients are begging for. If Metsera can offer strong enough weight loss in a once monthly shot that doesn’t make you sick for for half a month, they could truly be a disrupter.

Why this matters to you

If you’ve been denied by insurance. If your pharmacy has been out for months. If your doctor said no because you didn’t have diabetes. You know what it feels like to wait. You know how exhausting it is to watch the rich and famous get it while the rest of us ration and hope.

Metsera isn’t solving all that. Not yet. But they’re adding pressure. They’re building options. And if this next data hits, we could see meaningful competition shake up the duopoly.

So now what?

Remember the name MET 097i. Watch what happens in September. And keep your eyes on MET 233i too. It’s not just about weight loss anymore. It’s about building a medication that people can actually stay on.

Metsera will continue to be a fun one to watch.

Want more updates like this, straight from the patient’s point of view?

Join us at On The Pen, where we follow the obesity drug pipeline like your health depends on it, because for many of us, it does.

Subscribe